REGN


Roth Capital Reiterates Buy On Regeneron Following Two Year Data From Phase 3 VIVID-DME Trial

On Friday, Regeneron Pharmaceuticals (REGN) announced results from the Phase III VIVID-DME study of Eylea in DME that showed that treatment with Eylea 2 mg dosed …

Roth Capital Reiterates Buy On Regeneron Following Positive Data From Phase 2b Study

In a research note released today, Roth Capital analyst Joseph Pantginis reiterated coverage with a Buy rating on shares of Regeneron Pharmaceuticals (REGN) and a $382 price target, after REGN and partner …

Regeneron Remains A Strong Long Term Pick, Says Roth Capital Analyst

In a research note released Monday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals, Inc. (REGN) and a price target of $382.

Regeneron Has Solid Growth Prospects, Says Roth Capital Analyst

In a research note released this morning, Roth Capital reiterated coverage on Regeneron Pharmaceuticals (REGN) with a Buy rating and a price target of $382.00, following the announcement that …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts